# US 12,213,974 B2 · Methods of treating fibrosis > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,213,974 B2 - Document ID: US12213974B2 - Status: Granted - Kind: B2 - Application number: 18/755,445 - Filed: 2024-06-26 - Published: 2024-10-17 - Granted: 2025-02-04 - Earliest claimed: 2020-10-13 - Assignees: Endeavor BioMedicines, Inc. - Applicants: Endeavor BioMedicines, Inc. - Inventors: Miguel de los Rios; John Hood; Anita DiFrancesco; Luis A. Dellamary - Web page: https://patentgrep.com/patent/US12213974B2 ## CPC - A61K 31/497: containing further heterocyclic rings - A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 11/00: Drugs for disorders of the respiratory system - A61P 31/14: for RNA viruses - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment. ## Claims ### Claim 1 A method of treating idiopathic pulmonary fibrosis, the method comprising administering a dose of taladegib, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the dose of taladegib is selected from a dose in the range of 50 mg to 200 mg. ### Claim 2 (depends on 1) The method according to claim 1, wherein the dose of taladegib is selected from a dose in the range of 125 mg to 200 mg. ### Claim 3 A method of treating idiopathic pulmonary fibrosis, the method comprising administering a dose of taladegib, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the dose of taladegib is selected from a dose in the range of 100 mg to 300 mg. ### Claim 4 (depends on 3) The method according to claim 3, wherein the dose of taladegib is selected from a dose in the range of 100 to 300 mg/day. ### Claim 5 A method of treating idiopathic pulmonary fibrosis, the method comprising administering a dose of taladegib, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the dose of taladegib is selected from 25, 50, 75, 100, 150, 200, 250, 300, 350, and 400 mg. ### Claim 6 (depends on 5) The method according to claim 5, wherein the dose of taladegib is 50 mg. ### Claim 7 (depends on 6) The method according to claim 6, wherein the dose of taladegib is 50 mg/day. ### Claim 8 (depends on 5) The method according to claim 5, wherein the dose of taladegib is 100 mg. ### Claim 9 (depends on 8) The method according to claim 8, wherein the dose of taladegib is 100 mg/day. ### Claim 10 (depends on 5) The method according to claim 5, wherein the dose of taladegib is 200 mg. ### Claim 11 (depends on 10) The method according to claim 10, wherein the dose of taladegib is 200 mg/day. ### Claim 12 (depends on 5) The method according to claim 5, wherein the dose of taladegib is administered once a day. ### Claim 13 (depends on 1) The method according to claim 1, wherein the dose of taladegib is effective for slowing or halting progression of the idiopathic pulmonary fibrosis. ### Claim 14 (depends on 1) The method according to claim 1, wherein the dose of taladegib is effective for reducing impairment due to the idiopathic pulmonary fibrosis. ### Claim 15 (depends on 1) The method according to claim 1, wherein the dose of taladegib is effective for reversing impairment due to the idiopathic pulmonary fibrosis. ### Claim 16 (depends on 5) The method according to claim 5, wherein the dose of taladegib is effective for slowing or halting progression of the idiopathic pulmonary fibrosis. ### Claim 17 (depends on 5) The method according to claim 5, wherein the dose of taladegib is effective for reducing impairment due to the idiopathic pulmonary fibrosis. ### Claim 18 (depends on 5) The method according to claim 5, wherein the dose of taladegib is effective for reversing impairment due to the idiopathic pulmonary fibrosis. ### Claim 19 (depends on 1) The method according to claim 1, wherein taladegib is administered in the form of a pharmaceutical composition. ### Claim 20 (depends on 19) The method according to claim 19, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier, diluent, or excipient. ### Claim 21 (depends on 19) The method according to claim 19, wherein the pharmaceutical composition comprises HPMCAS-H, mannitol, microcrystalline cellulose, croscarmellose sodium, silicon dioxide, and sodium stearyl fumarate. ### Claim 22 (depends on 5) The method according to claim 5, wherein taladegib is administered in the form of a pharmaceutical composition. ### Claim 23 (depends on 22) The method according to claim 22, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier, diluent, or excipient. ### Claim 24 (depends on 22) The method according to claim 22, wherein the pharmaceutical composition comprises HPMCAS-H, mannitol, microcrystalline cellulose, croscarmellose sodium, silicon dioxide, and sodium stearyl fumarate. ### Claim 25 (depends on 5) The method according to claim 5, wherein the dose of taladegib is 25 mg. ### Claim 26 (depends on 25) The method according to claim 25, wherein the dose of taladegib is 25 mg/day.